Antibodies, detection systems and accessories for immunohistochemistry
Probes, kits and detection systems – visualizing DNA and RNA in tissue sections
Real-time PCR, Next Generation Sequencing (NGS) and DNA arrays – careful analysis, reliable detection
Staining machines for immunohistochemistry and a machine for in-situ hybridisation
Complete blocks, slide sets and individual tissue arrays – for routine and research
We are a Berlin-based company specializing in the development, manufacture and distribution of diagnostic reagents and system solutions for immunohistology, in situ hybridization and molecular pathology.
Consistent high quality is a top priority. This is why development and manufacturing of our products are governed by a quality management system certified to ISO 9001:2015 and ISO 13485:2016. A majority of the Zytomed Systems products are CE labelled and are approved as reagents for in vitro purposes (CE/IVD). See the download section for our certificates.
At Zytomed Systems we will be also compliant with the IVDR requirements.
Learn moreEthically correct, respectful dealing with our business partners is of very high importance to Zytomed Systems GmbH and a matter of course. This includes all commercial, legal and interpersonal levels, concerns and aspects.
Learn moreThanks to our extensive network of distribution partners, you can order our products from anywhere in the world. The high degree of satisfaction of our customers speaks for itself. Our aim is to precisely tailor our products to your needs. Rely on our many years of experience, our quality, flexibility and excellent service.
Learn moreBreast cancer is one of the most common cancers in women worldwide. In Germany, every 8th woman is diagnosed with breast cancer. Until now, therapies have been based on the presence/absence of (hormone) receptors or the Her2 receptor in metastatic/non-metastatic breast cancer.
Detection of mutations and fusions in the FGFR1, FGFR2, FGFR3 and FGFR4 genes
In May 2024 the S3 guideline "Prostate Cancer" (version 7.0) was updated. For the first time it is recommended to sequence genes involved in homologous recombination repair (HRR), e. g. ATM, BRCA1/2, BRIP1, CDK12, CHEK2, FANCA, HDAC2 and PALB2, before initiating a systemic therapy for castration-resistant prostate cancer (mCRPC).
Today, we are proud to announce that ZytoVision, our sister company, received the IVDR certification!